WGRX Stock Risk & Deep Value Analysis
Wellgistics Health Inc
Healthcare • Pharmaceutical Retailers
DVR Score
out of 10
What You Need to Know About WGRX Stock
We analyzed Wellgistics Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran WGRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
WGRX Risk Analysis & Red Flags
What Could Go Wrong
The company could fail to execute its planned reverse stock split, or even if executed, fail to maintain Nasdaq's minimum bid price requirement by the June 8, 2026 deadline, resulting in delisting. This would severely impair liquidity, investor confidence, and access to capital, making a recovery or strategic pivot nearly impossible.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Complete absence of recent quarterly financial reports (10-Q) indicating severe transparency issues.
- ⚠
Imminent Nasdaq delisting threat due to minimum bid price deficiency (June 8, 2026 deadline).
- ⚠
Raised $1.25M via 0% promissory notes, indicating immediate need for capital and adding debt.
- ⚠
Non-binding, all-stock LOI for Neuritek Therapeutics suggests future dilution and high integration risk without clear valuation.
- ⚠
Current market cap and share price indicate a distressed penny stock, highly susceptible to volatility.
Upcoming Risk Events
- 📅
Failure to regain Nasdaq compliance leading to delisting (June 8, 2026 deadline)
- 📅
Failure to secure sufficient additional financing beyond current promissory notes
- 📅
Neuritek Therapeutics acquisition falling through or not delivering anticipated value
- 📅
Negative impact of promissory note covenants on future financing or operations
When to Reconsider
- 🚪
Official announcement of delisting from Nasdaq.
- 🚪
Failure to close the Neuritek Therapeutics acquisition or significant negative news regarding the deal.
- 🚪
Further significant share dilution without demonstrable value creation or revenue growth.
- 🚪
Any public filing indicating continued lack of financial transparency or going concern issues.
Unlock WGRX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Wellgistics Health Inc (WGRX) Do?
Market Cap
$105.12M
Sector
Healthcare
Industry
Pharmaceutical Retailers
Wellgistics Health, Inc. engages in the wholesale and distribution of pharmaceutical products to pharmaceutical manufacturers and independent retail pharmacies in the United States. The company distributes generic and branded pharmaceuticals, as well as over-the-counter healthcare and consumer products. It also offers third-party logistics services that include warehousing, inventory management, pick and pack, and shipping to small and mid-size pharmaceutical manufacturers. It also operates DelivMeds platform that serves as a pharmaceutical hub to facilitate the transfer of prescriptions and provide backend clinical concierge services to a network of independent pharmacies; and operates a retail community specialty. The company was formerly known as Danam Health, Inc. and changed its name to Wellgistics Health, Inc. in October 2024. Wellgistics Health, Inc. was incorporated in 2022 and is based in Tampa, Florida.
Visit Wellgistics Health Inc WebsiteInvestment Thesis
An extremely high-risk, lottery-ticket investment. The bull case hinges entirely on WGRX successfully navigating its imminent Nasdaq delisting threat via a reverse split, executing the non-binding all-stock acquisition of Neuritek Therapeutics, and then rapidly leveraging Neuritek's potential neuroscience pipeline into a viable, profitable business. This requires flawless execution, significant future funding, and a complete reversal of its current opaque financial state, all within a compressed timeframe.
Is WGRX Stock Undervalued?
Unlock the full AI analysis for WGRX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
WGRX Price Targets & Strategy
12-Month Target
$0.05
Bull Case
$0.50
Bear Case
$0.00
Valuation Basis
No reliable valuation can be performed due to the complete absence of recent financial reporting. The target reflects a high probability of further decline or delisting if current issues are not resolved. Upside scenario assumes successful reverse split, Nasdaq compliance, and closing/integration of Neuritek, valuing at ~$60M market cap post-reverse split.
Entry Strategy
Extreme caution is advised. Only consider entry after the company demonstrates Nasdaq compliance, closes the Neuritek acquisition, and provides transparent, positive financial reporting. Any entry at current levels (around $0.12) is highly speculative and effectively a lottery ticket.
Exit Strategy
If delisted, consider full exit. If significant positive news (e.g., successful reverse split *and* Nasdaq compliance *and* Neuritek acquisition closes *and* positive financial reporting) drives the price above $0.50, consider taking profits. Stop loss at $0.05 due to high risk of complete loss.
Portfolio Allocation
0% for conservative/moderate risk tolerance. Max 0.1% for aggressive, highly speculative portfolios, acknowledging potential for complete loss.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is WGRX Financially Healthy?
Valuation
P/E Ratio
-1.90
Price/Book
27.96
Price/Sales
0.57
Profitability
Gross Margin
-214.30%
Revenue Growth
-44.55%
EPS
$-1.00
Balance Sheet
Current Ratio
0.32
Quick Ratio
0.10
Debt/Equity
27.22
Does WGRX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Not applicable
There is no identifiable economic moat. The company operates in a highly competitive and regulated industry where success requires significant capital, R&D, and strong intellectual property, none of which are evident or robustly established for Wellgistics.
Moat Erosion Risks
- •Intense competition from larger, well-funded pharmaceutical and biotech companies.
- •Lack of proprietary technology or strong intellectual property to protect products.
- •High capital requirements to develop and market new drugs/health products.
WGRX Competitive Moat Analysis
Sign up to see competitive advantages
WGRX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral/Bearish. The extremely low share price and high risk profile likely deter positive sentiment, with speculation largely tied to survival rather than growth.
Institutional Sentiment
Negative. The absence of analyst coverage or institutional ownership data, combined with imminent delisting risk, suggests institutional investors are largely absent or bearish.
Insider Activity (Form 4)
Two new directors, Eric Michael Sherb and Herman Gary L, filed Form 3s (initial statements) on April 9, 2026. No Form 4 filings for buys or sells by any insiders within the last 90 days were reported.
Options Flow
Normal options activity. No specific unusual options activity or significant put/call ratio skew reported in the provided data.
Earnings Intelligence
Next Earnings
No expected date available; no recent quarterly earnings report (10-Q) found.
Surprise Probability
Low (given lack of reporting and fundamental financial distress)
Historical Earnings Pattern
No historical earnings reaction patterns can be established due to the lack of available earnings reports.
Key Metrics to Watch
Competitive Position
Top Competitor
XBIT
Market Share Trend
Unknown. No data on current products or market share provided.
Valuation vs Peers
Impossible to compare valuation metrics (P/E, EV/EBITDA, P/S) due to the complete lack of financial reporting for WGRX. Small-cap biotech peers (e.g., Xequel Bio, Cortexyme, similar micro-cap neuroscience firms) would typically trade on pipeline potential and cash runway, neither of which can be assessed for WGRX.
Competitive Advantages
- •None identifiable from provided data. Potential future advantage from Neuritek's IP if acquired, but details are unknown.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive WGRX Stock Higher?
Near-Term (0-6 months)
- •Execution of 1:25 to 1:200 reverse stock split (Board discretion, within 12 months)
- •Resolution of Nasdaq minimum bid price deficiency (Deadline June 8, 2026)
- •Potential closing and definitive agreement for Neuritek Therapeutics Inc. acquisition (non-binding LOI)
Medium-Term (6-18 months)
- •First post-acquisition financial reporting for combined entity (if Neuritek deal closes)
- •Progress on pipeline development within Neuritek Therapeutics (if acquired)
Long-Term (18+ months)
- •Achieving sustainable market leadership in specific neuroscience segments (highly speculative)
- •Establishing consistent revenue growth and profitability post-pivot
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for WGRX?
- ✓
Confirmation of Nasdaq compliance and continued listing.
- ✓
Successful closing of the Neuritek Therapeutics acquisition with clear, favorable terms.
- ✓
Issuance of full, transparent, and positive quarterly financial reports.
- ✓
News of successful clinical trials or regulatory milestones for acquired Neuritek assets.
Bull Case Analysis
See what could go right with Premium
Competing with WGRX
See how Wellgistics Health Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Wellgistics Health Inc WGRX | $105.1M | 0.5 | -1.9 | $3.0M | 0.0% | -44.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Wellgistics Health Inc Makes Money
Wellgistics Health Inc. appears to be a health products company that, based on prior indications and the recent non-binding Letter of Intent (LOI) to acquire Neuritek Therapeutics Inc., is attempting a strategic pivot into neuroscience drug development. Previously, the company had some operational activities, including a direct-to-consumer (DTC) focus and the launch of a product called Forzet. If the Neuritek acquisition closes, its business model would shift towards developing and potentially commercializing therapeutics for neurological conditions, leveraging Neuritek's assets.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Wellgistics Health Inc (WGRX)?
As of April 11, 2026, Wellgistics Health Inc has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Wellgistics Health Inc?
Wellgistics Health Inc's market capitalization is approximately $105.1M. The company operates in the Healthcare sector within the Pharmaceutical Retailers industry.
What ticker symbol does Wellgistics Health Inc use?
WGRX is the ticker symbol for Wellgistics Health Inc. The company trades on the NCM.
What is the risk level for WGRX stock?
Our analysis rates Wellgistics Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of WGRX?
Wellgistics Health Inc currently has a price-to-earnings (P/E) ratio of -1.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Wellgistics Health Inc's revenue growing?
Wellgistics Health Inc has reported revenue growth of -44.5%. Revenue has been declining, which warrants closer examination.
Is WGRX stock profitable?
Wellgistics Health Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the WGRX DVR analysis updated?
Our AI-powered analysis of Wellgistics Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for WGRX (Wellgistics Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.